Table 1.
Serum creatinine criteria for defining and staging AKI*.
Figure 1.
Flow chart showing the total cohort, excluded patients and stratification by AKI severity grade according to the AKI criteria used (KDIGO or RIFLE).
AMI, acute myocardial infarction; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.
Table 2.
Baseline clinical characteristics and medical therapy during hospitalization.
Table 3.
Baseline clinical characteristics and medical therapy during hospitalization of AKI versus non-AKI patients according to the two AKI criteria used.
Table 4.
Univariate analyses for mortality at 30 days and 1-year and comparison between patients who developed and did not develop AKI according to the different AKI definitions.
Figure 2.
Hazard ratio (Cox multivariate analysis) for death at 30 days and at 30-day to 1-year follow-up according to the different AKI criteria.
AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.
Figure 3.
Cox survival curve at 30 days according to the different AKI criteria.
A. RIFLE; B. KDIGO; C. KDIGO but not RIFLE. AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.
Figure 4.
Cox survival curve at 30-days to 1-year according to the different AKI criteria.
A. RIFLE; B. KDIGO; C. KDIGO but not RIFLE. AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.
Table 5.
Cox proportional hazard models for the association between 30-day mortality and AKI according to the different AKI criteria used.
Table 6.
Cox proportional hazard models for the association between 30-day to 1-year mortality and AKI according to the different AKI criteria used.